Daniel Kantor, MD, discussed the data from his presentation at the 2022 CMSC annual meeting on COVID-19 vaccine response in patients with multiple sclerosis, and what questions are still lingering among the clinical community.
Daniel Kantor, MD
Advertisement
President, Kantor Neurology; President Emeritus, Florida Society of Neurology
Articles by Daniel Kantor, MD
Daniel Kantor, MD, discussed his presentation at the 2022 CMSC annual meeting on COVID-19 vaccine response in patients with multiple sclerosis who are being treated with sphingosine 1 phosphate receptor modulators.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related Amyloid Pathology
2
Inside the Phase 3 MASCOT Trial: Lundbeck’s Push for the First Disease-Modifying MSA Therapy
3
Phase 2 OPAL Study to Test Muscle-Targeting Therapy Apitegromab in Infants With SMA
4
Decision-Making in De-Escalating Therapy for Multiple Sclerosis
5
